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Abstract 
Fundus autofluorescence (FAF) is a non-invasive retinal imaging modality used in clinical practice to provide a density 
map of lipofuscin, the predominant ocular fluorophore, in the retinal pigment epithelium. Multiple commercially 
available imaging systems, including the fundus camera, the confocal scanning laser ophthalmoscope, and the 
ultra-widefield imaging device, are available to the clinician. Each offers unique advantages for evaluating various 
retinal diseases. The clinical applications of FAF continue to expand. It is now an essential tool for evaluating age 
related macular degeneration, macular dystrophies, retinitis pigmentosa, white dot syndromes, retinal drug toxici-
ties, and various other retinal disorders. FAF may detect abnormalities beyond those detected on funduscopic exam, 
fluorescein angiography, or optical coherence tomography, and can be used to elucidate disease pathogenesis, 
form genotype-phenotype correlations, diagnose and monitor disease, and evaluate novel therapies. Given its ease 
of use, non-invasive nature, and value in characterizing retinal disease, FAF enjoys increasing clinical relevance. This 
review summarizes common ocular fluorophores, imaging modalities, and FAF findings for a wide spectrum of retinal 
disorders.
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Background
Fundus autofluorescence (FAF) is a non-invasive imaging 
technique that detects fluorophores, naturally occurring 
molecules that absorb and emit light of specified wave-
lengths [1]. To produce autofluorescence, a fluorophore 
absorbs a photon of the excitation wavelength, which 
elevates an electron to an excited, high energy state. 
The electron dissipates some energy through molecu-
lar collisions, then emits a quantum of light at a lower 
energy and longer wavelength as it transitions back to 
ground state. Classically, FAF utilizes blue-light excita-
tion, then collects emissions within a preset spectra to 
form a brightness map reflecting the distribution of lipo-
fuscin, a dominant fluorophore located in the RPE. FAF 
may use other excitation wavelengths to detect addi-
tional fluorophores, such as melanin with near-infrared 
autofluorescence.
First described by Delori in the 1980s, FAF has since 
expanded in both scope and practice [1]. Given the 
unique findings not identified with funduscopic exami-
nation, fundus photography, or fluorescein angiography, 
FAF is useful in the evaluation of a diverse spectrum of 
diseases involving the retina and RPE, including degen-
erative, dystrophic, inflammatory, infectious, neoplastic, 
and toxic etiologies. This review summarizes the known 
ocular fluorophores, various imaging modalities, and 
broad clinical applications of FAF.
Ocular fluorophores: lipofuscin, A2E, and other 
ocular fluorophores
Lipofuscin
Located in the RPE, lipofuscin is a dominant macular 
fluorophore that absorbs blue light with a peak excitation 
wavelength of 470 nm and emits yellow–green light at a 
peak wavelength of 600–610 nm (Fig. 1) [2]. Lipofuscin is 
a heterogeneous mixture and derives its autofluorescent 
properties from bisretinoid compounds, which are meta-
bolic byproducts of vitamin A and the visual cycle.
Open Access
International Journal
of Retina and Vitreous
*Correspondence:  dsarraf@ucla.edu 
2 Greater Los Angeles VA Healthcare Center, Los Angeles, CA 90024, USA
Full list of author information is available at the end of the article
Page 2 of 25Yung et al. Int J Retin Vitr  (2016) 2:12 
Bisretinoids are initially formed in photoreceptor outer 
segments and then deposited in the RPE as lipofuscin, 
accumulating in RPE lysosomes with age [1]. Lipofus-
cin also increases in degenerative disorders, including 
age-related macular degeneration (AMD), and macular 
dystrophies such as Best and Stargardt disease [3]. The 
distribution of lipofuscin, and consequently the distri-
bution of autofluorescence, is greatest in the posterior 
pole but limited in the fovea, and decreases toward the 
periphery [1, 4].
A2E
N-Retinyl-N-retinylidene ethanolamine (A2E) is the first 
and best characterized component of lipofuscin, with 
excitation at 430–450  nm and maximum emission at 
560–575  nm [5]. A pyridium bisretinoid, A2E is enzy-
matically indigestible, accumulates in RPE lysosomes, 
exerts multiple toxic effects on RPE cells in  vitro, and 
has been implicated in multiple degenerative retinal 
diseases. When irradiated by blue-light, A2E undergoes 
photo-oxidation and generates reactive oxygen species 
[6–10]. In addition, A2E has been shown to interfere 
with cholesterol metabolism, destabilize cell membranes, 
damage DNA, and trigger apoptosis [11–13]. However, 
other studies suggest that A2E may in fact protect the 
retina from photo-oxidative stress. A2E generates sin-
glet oxygen species much less effectively than its precur-
sor all-trans-retinal, and conversion to A2E may protect 
the retina from the toxic effects of all-trans-retinal. A2E 
accumulation may be merely a marker for aberrant vis-
ual cycle activity, rather than the source of retinal dam-
age [14, 15]. In addition, A2E is distributed peripherally 
in human eyes, rather than centrally, like lipofuscin, sug-
gesting that A2E may not be the dominant fluorophore 
responsible for increased macular FAF over time [16–18]. 
Given these mixed results, the role of A2E in retinal dis-
ease appears complex and requires further study to fully 
elucidate its function.
Other ocular fluorophores
Other clinically significant fundus fluorophores include 
vitelliform lesions and optic disc drusen. Vitelliform 
lesions refer to the clinical finding of round, yellow, reti-
nal lesions reminiscent of an egg yolk. While lipofuscin is 
located within RPE lysosomes, vitelliform lesions consist 
of extracellular fluorophores—shed outer segment debris 
Fig. 1 Excitation and emission spectra of common retinal imaging modalities. Fluorescein angiography and fundus autofluorescence operate in 
the blue–green spectra of visible light, while indocyanine green angiography (ICG) utilizes the infrared spectra. The crystalline lens, a common 
source of interference, has an emission peak similar to that of lipofuscin. With kind permission from Springer Science + Business Media: Atlas of 
Fundus Autofluorescence Imaging, Chapter 5: Autofluorescence Imaging with the Fundus Camera, 2007, pp. 49–54, Spaide, Fig. 5.1
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in the subretinal extracellular space, which accumulate 
due to RPE dysfunction and loss of apposition between 
photoreceptor tips and the RPE [19–21].
Optic disc drusen are deposits of extracellular mito-
chondria in a filamentous protein matrix and if superfi-
cial, may produce increased FAF [22]. These lesions may 
be associated with visual field defects, optic nerve dys-
function, and various vitreoretinal conditions including 
retinitis pigmentosa, Alagille syndrome, and pseudoxan-
thoma elasticum [23].
Structures anterior to the retina, including the cornea 
and lens, naturally emit autofluorescence and can cause 
interference, decreasing image resolution in FAF sys-
tems. The cornea has an excitation peak at 365–480 nm 
and an emission peak at 620 nm [24], while the lens has 
an excitation peak at 420–430 nm and an emission peak 
at 520  nm [25]. Diseases involving these structures can 
further impact FAF findings. For example, corneal auto-
fluorescence increases in patients with diabetes and is 
thought to result from the accumulation of advanced gly-
cation products [26, 27]. Cataracts increase light absorp-
tion and scatter by the lens, leading to poor contrast 
autofluorescence images that improves with cataract 
extraction and intraocular lens placement [28, 29].
In order to minimize interference from the lens and 
cornea, fundus cameras have adopted barrier filters with 
red-shifted wavelengths. Confocal scanning laser oph-
thalmoscopes (cSLO) utilize confocal optics in the form 
of a spatial pinhole that collects light from a single optical 
plane at the level of the fundus while eliminating out-of-
focus light [30–32].
Melanin
Melanin is an ocular pigment located in the both RPE 
cells and in uveal melanocytes. In the fundus, melanin is 
distributed primarily in the fovea, macula, and periph-
ery [4]. Within RPE cells, melanin granules are located 
apically and lipofuscin basolaterally [33, 34]. In contrast 
to lipofuscin, melanin has a peak excitation at a longer 
wavelength of 787  nm and is the primary fluorophore 
in near-infrared autofluorescence [35]. On conventional 
FAF, melanin absorbs the short-wavelength excitation 
beam, decreasing the overall autofluorescent signal [5].
Melanin protects the retina from light-induced damage 
in several ways [36]. Melanin located in anterior segment 
structures such as the iris absorb and block visible light 
and UV radiation, shielding the retina from excessive 
light energy. In addition, RPE melanin acts as an anti-
oxidant, protecting against free radicals, redox-reactive 
heavy metals, photo-oxidation, and lipofuscin accumula-
tion [37–41], although this effect decreases with age and 
melanin may even gain pro-oxidant properties over time 
[40]. Individuals with lightly pigmented irises [42–44] 
and decreased RPE melanin content [45] demonstrate 
a higher incidence and severity of age-related macular 
degeneration.
Rhodopsin
Rhodopsin is a visual pigment concentrated in rod pho-
toreceptor outer segments that absorbs the excitation 
beam and decreases autofluorescence [46]. However, 
with continued exposure to light, rhodopsin undergoes 
photo-isomerization and loses its absorptive capabili-
ties, resulting in a progressive increase in autofluores-
cent signal [47]. Termed the bleaching effect, rhodopsin 
absorption and photo-isomerization is seen with short-
wavelength, but not near-infrared, excitation beams. 
Compared to dark-adapted eyes in which rhodopsin is 
maximally active, FAF can increase over 30 % after expo-
sure to light that strongly bleaches rhodopsin (Fig. 2) [48]. 
Changes in optical density due to the bleaching effect are 
decreased in retinal dystrophies involving photoreceptor 
dysfunction, including cone-rod dystrophy, Stargardt dis-
ease, and choroideremia [49].
Commonly used fundus autofluorescence (FAF) 
imaging systems
Commercially available FAF systems include fundus cam-
eras, confocal scanning laser ophthalmoscopes (cSLO), 
and ultra-widefield technologies (Table  1). Limitations 
of FAF include a low signal strength (two orders of mag-
nitude less than the peak signal of fluorescein angiogra-
phy) and autofluorescence artifact from anterior segment 
structures. In addition, the blue-light excitation beam 
may cause patient discomfort and be potentially toxic 
to the retina, although there have been no formal stud-
ies demonstrating the adverse effects of FAF. The various 
imaging modalities have utilized different strategies to 
address these shortcomings.
Fundus camera
The fundus camera is a digital system that captures auto-
fluorescence using a single flash of light (Fig.  3a) [50]. 
Commercially available models are produced by Top-
con®, Zeiss®, and Canon® (Table 1). To reduce autofluo-
rescence of the lens and cornea, Spaide introduced the 
‘modified Topcon’ filter set with red-shifted wavelengths, 
with an excitation spectra of 535–585 and a 615–715 nm 
emission barrier filter [51].
The use of the red-shifted wavelengths by fundus cam-
eras decreases absorption by macular pigments, allow-
ing detection of subtle perifoveal RPE changes [50]. This 
excitation spectra also decreases absorption by the crys-
talline lens, preserving image quality in cases of cataract. 
In fact, fundus cameras demonstrate reduced image deg-
radation and higher rates of successful image acquisition 
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in patients with cataracts compared to cSLOs [52, 53]. 
Fundus cameras also provide better detection of exuda-
tive retinal disease such as choroidal neovascularization 
or central serous chorioretinopathy compared to cSLOs 
[54]. However, even with modification, fundus cameras 
capture more reflected and scattered light compared to 
confocal systems [53, 55]. Scattered light from structures 
outside the retinal plane may falsely increase the FAF sig-
nal, a phenomena termed pseudo-autofluorescence [54].
Because the excitation spectra of fundus cameras dif-
fers from that of fluorescein angiography, the two imaging 
modalities can be used in any order without interference 
[55]. Additional advantages of fundus cameras include 
color imaging capability and greater resistance to motion 
artifact in cases of poor fixation. The single flash expo-
sure of flood light illumination is more comfortable 
for the patient but produces images with low contrast, 
although photographers may manually acquire several 
images for image averaging or utilize image manipulation 
methods to improve contrast. Fundus cameras are less 
expensive than confocal scanning laser ophthalmoscopes 
(cSLOs), but require post-purchase modifications such as 
the installation of filters.
Confocal scanning laser ophthalmoscope (cSLO)
cSLO systems utilize a system of mirrors to focus a low 
power laser in a two-dimensional raster pattern onto the 
fundus (Fig.  3b). Platforms use a blue excitation wave-
length of 488  nm and detect emission wavelengths of 
500–700  nm [56]. Confocal optics reduce light detec-
tion to a single optical plane, eliminating scattered light 
and interference from structures outside the retina, such 
as the crystalline lens [57]. cSLO systems offer real-time 
averaging, where typically nine to sixteen images are 
averaged to produce high-contrast and high-resolution 
images. There is no limit to the number of images aver-
aged [50]. However, real-time averaging may lead to loss 
of information, especially in patients with poor fixation 
and excessive eye movement [50]. cSLO imaging cannot 
be preceded by fluorescein angiography, which has a sim-
ilar excitation and emission spectra. A substantial frac-
tion of the excitation beam is also absorbed by macular 
pigments, which have absorption spectra similar to the 
excitation beam wavelength [58].
Commercially available cSLO systems include the Hei-
delberg Spectralis® and the Nidek F-10®. The Heidelberg 
retinal angiograph® (HRA), now available as the Heidel-
berg Spectralis®, uses a barrier filter of 500 nm and offers 
20–55 degree images. Other cSLO systems include the 
Zeiss prototype SM 30 4024® (ZcSLO) with a barrier fil-
ter of 521 nm and the Rodenstock cSLO® (RcSLO) with a 
barrier filter of 515 nm, though these are no longer com-
mercially available. A comparison of the HRA®, ZcSLO®, 
and RcSLO® demonstrates that HRA® takes the brightest 
images, while the RcSLO® captures the darkest images 
with the lowest contrast [59]. The level of background 
noise was lowest for HRA® and highest for ZcSLO [59]. 
The Nidek F-10® digital ophthalmoscope offers blue light 
FAF at 490 nm, fluorescein angiography, and indocyanine 
green angiography [60]. In addition, infrared imaging at 
700  nm using Retro-mode on the Nidek F-10®, which 
relies on laterally scattered light, is more sensitive for 
drusen than conventional color fundus photography [61, 
62].
Fig. 2 Bleaching effect of rhodopsin. Immediately after obtaining a 30 degree FAF (a), the 50 degree FAF (b) shows a discrete area of relative hyper-
autofluorescence corresponding to an area of bleached photoreceptors resulting from the first image acquisition
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FAF images are monochromatic and lack the color 
information of fundus photography. cSLO systems such 
as the Heidelberg Spectralis® do offer reflectance-based 
MultiColor® imaging, which can be used in conjunction 
with SD-OCT. This technology simultaneously acquires 
reflectance images at three different wavelengths: blue 
(486  nm), green (518  nm), and infrared (815  nm), and 
then superimposes the images to form a final multi-
colored image [63]. Recently, LaRocca and colleagues 
introduced a “true color” SLO using a supercontinuum 
laser [64]. However, these techniques use fundus reflec-
tance imaging, and there are currently no color options 
for FAF.
cSLO systems can be used reliably to quantify macular 
pigment density, which consists of lutein, zeaxanthin, and 
meso-zeaxanthin [65]. With an absorption spectrum of 
400–540  nm and peaking at 460  nm, macular pigments 
filter blue light and also act as antioxidants to protect 
the retina [66, 67]. Changes in macular pigment density 
may reflect visual function and retinal diseases such as 
age-related macular degeneration [68, 69]. To measure 
macular pigment, cSLOs such as the Heidelberg Spectra-
lis® utilize dual-wavelength autofluorescence, which uses 
lipofuscin autofluorescence as an indirect measure of 
macular pigment density. Averaged images are obtained 
at two excitation wavelengths, 488 and 514  nm, using 
a barrier filter above the macular pigment absorption 
wavelength (e.g. 530 nm). These images are then digitally 
subtracted from each other to construct a map of macu-
lar pigment density [70]. Variations of this FAF technique 
include using only one high absorption wavelength to 
obtain images, using a fundus camera instead of a cSLO, 
and inferring macular pigment density by comparing 
foveal and para-foveal autofluorescence [70]. Besides 
FAF, other methods used to measure macular pigment 
density include motion photometry, heterochromatic 
flicker photometry, resonance Raman spectroscopy, and 
fundus reflectance [65].
Although cSLO and fundus cameras use different exci-
tation and emission wavelengths, the two systems are 
largely concordant on retinal pathology given the wide 
autofluorescent spectra of lipofuscin. While the fundus 
camera has lower cost and shorter image acquisition 
time, studies suggest superior images are obtained with 
cSLO in 70 % of cases [50].
Optos ultra‑widefield system
The Optomap Ultra-Widefield® system by Optos® com-
bines confocal scanning laser technology with an ellip-
soid mirror to achieve up to 200 degrees of view (82.5 % 
of retinal surface area) of the ocular fundus (Fig. 3c) [71]. 
The Optos® system simultaneously uses two excitation 
wavelengths of red (633  nm) and green (532  nm) light 
with an emission filter of >540  nm [48]. Similar to the 
fundus camera, the longer wavelength spectra of this sys-
tem reduces absorption by macular pigment and allows 
for a clear image after fluorescein angiography.
Ultra-widefield imaging allows for improved detec-
tion and analysis of many pathologic retinal conditions 
with peripheral findings, including diabetic retinopathy 
and other retinal vascular diseases, age-related macu-
lar degeneration, and myopic degeneration [72]. The 
Optos® system has several important features, includ-
ing the ability to acquire images through a native non-
dilated pupil, a brief image acquisition time (250  ms), 
and the option of pseudocolor fundus photography 
[48]. However, use of the ellipsoid mirror in the Optos® 
system distorts the peripheral retina, creating a topo-
graphic mismatch, and the view is limited superiorly 
and inferiorly [73]. The Optos® system is also limited by 
Fig. 3 Comparison of common imaging systems available for fundus autofluorescence. Images of normal, healthy retina were obtained using the 
fundus camera with a Spaide filter (a), confocal cSLO (b), and Optos ultra-widefield systems (c)
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lid and eyelash artifact, lack of real-time averaging, and 
poor contrast.
Other modern ultra‑widefield imaging systems
The Heidelberg Retinal Angiograph® system can be mod-
ified for widefield imaging with the Staurenghi® lens, 
which provides 150 degrees of view. This system is lim-
ited by lens artifact and requires placement of a contact 
lens by an experienced photographer [74]. More recently, 
Heidelberg® debuted a non-contact, ultra-widefield sys-
tem that provides a 105 degree view and is manually 
attached to the camera [75]. In contrast to the Optos® 
ellipsoid mirror, the Heidelberg ultra-widefield® system 
allows for high contrast, non-distorted images without 
lid and eyelash artifact [75]. The Heidelberg® system has 
a smaller field of view compared to the Optos® system, 
especially in the nasal and temporal quadrants [72].
Fundus autofluorescence imaging in clinical 
practice
The signal intensity on FAF images depends on the con-
centration of lipofuscin and to a smaller degree, other 
fluorophores as discussed above. Lesions can be catego-
rized as hyper-autofluorescent (Fig.  4a), hypo-autofluo-
rescent (Fig. 4b), or iso-autofluorescent, and result from 
various retinal pathological mechanisms.
Autofluorescent patterns result from the complex inter-
action of fluorophores such a lipofuscin, which release an 
autofluorescent signal, and elements such as melanin and 
rhodopsin, which absorb the excitation beam and attenu-
ate autofluorescence. Other structures such as retinal 
vessels and the crystalline lens may also influence auto-
fluorescence through blocking and interference. Spatial 
variations in normal background autofluorescence reflect 
the distribution of lipofuscin and other fluorophores, 
which in turn reflect the distribution of photoreceptors 
and RPE cells. Meanwhile, the overall intensity of the 
autofluorescent signal is determined by individual factors 
such as age [5], light exposure [76], genotype, etc.
A large portion of hyper-autofluorescent lesions results 
from alterations in lipofuscin metabolism. Accumulation 
of lipofuscin in RPE cells, accumulation of bisretinoids 
in photoreceptor outer segments, and photooxidation of 
bisretinoids in lipofuscin can all contribute to enhanced 
autofluorescence [77]. Specific mechanisms vary by dis-
ease, ranging from the inability to clear bisretinoids 
from photoreceptor cells in Stargardt disease [78] to 
superimposed RPE cells in geographic atrophy (GA) of 
age-related macular degeneration (AMD) [79]. Accu-
mulation of subretinal vitelliform material in Best dis-
ease, adult onset vitelliform maculopathy, and other 
acquired vitelliform disorders is another classic etiology 
of hyper-autofluorescence. Hyper-autofluorescence can 
also result from a window defect due to loss of rhodop-
sin, which normally absorbs the excitation wavelength 
and decreases autofluorescence. Rhodopsin attenuation 
and hyper-autofluorescence can occur physiologically as 
seen in the bleaching effect. In disease, photoreceptor 
degeneration and loss of rhodopsin unmasks the auto-
fluorescent signal of the underlying RPE, creating hyper-
autofluorescent lesions such as in white dot syndromes 
and other pathologies [80]. Fluorophores other than lipo-
fuscin, including optic disc drusen, can also form hyper-
autofluorescent lesions.
In contrast, hypo-autofluorescence can arise from 
decreased lipofuscin or blockage by material anterior 
to the RPE/photoreceptors. Perhaps the most strik-
ing example of hypo-autofluorescence due to decreased 
lipofuscin is the absence of autofluorescence at the site 
of RPE tears, where the RPE is completely denuded [81]. 
Other pathologies involving decreased lipofuscin include 
RPE atrophy in GA and visual cycle defects in fundus 
albipunctatus. Meanwhile, blockage can occur from any 
material anterior to the RPE/photoreceptors, including 
physiologic structures such as blood vessels and macular 
pigments, and pathologic structures such as media opaci-
ties, intraretinal or subretinal hemorrhage, and fibrosis.
Age‑related macular degeneration
Affecting 6.5 % of Americans over 40 years old, AMD can 
be associated with vision loss in both non-neovascular and 
neovascular forms of disease [82]. FAF can be an impor-
tant tool to monitor non-neovascular AMD—especially 
GA, the second most important etiology of severe vision 
loss in AMD after choroidal neovascularization [83].
In early non-neovascular AMD, FAF may show hyper 
and hypo-autofluorescent areas that reveal more wide-
spread disease than appreciated with fundoscopy or color 
photography. Hyperpigmented lesions may represent 
melanin granules, which correlate with hypo-autofluo-
rescence, or melanolipofuscin granules, which correlate 
with hyper-autofluorescence [84]. Depigmented, hypo-
autofluorescent areas correspond to RPE atrophy, which 
may signal early geographic atrophy [84, 85]. In 2005, 
the International FAF Classification Group defined eight 
phenotypic FAF patterns associated with early non-neo-
vascular AMD: normal, minimal change, focal increase, 
patchy, linear, lace-like, reticular, and speckled [86].
Drusen
Drusen have an extremely variable appearance on FAF 
depending on size, composition, and health of the overly-
ing RPE and ellipsoid layer [87]. Large drusen are more 
likely to result in FAF changes, while small drusen may 
be iso-autofluorescent and remain undetected [88]. Inter-
mediate drusen (63–125 µm in diameter) demonstrate a 
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Fig. 4 a Causes of hyper-autofluorescence. b Causes of hypo-autofluorescence
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pattern of central hypo-autofluorescence with an annulus 
of hyper-autofluorescence, likely due to central RPE atro-
phy surrounded by abnormal RPE [89]. Cuticular drusen, 
associated with vitelliform macular detachment and 
described as multiple dense nodules creating a “stars in 
the sky appearance” with fluorescein angiography, appear 
hypo-autofluorescent with FAF [90]. Crystalline drusen 
also appear hypo-autofluorescent due to associated RPE 
atrophy [85].
Hyper-autofluorescent lesions include large, soft con-
fluent drusen and drusenoid pigment epithelial detach-
ments (PED) [88]. Drusenoid PEDs typically appear as 
a foci of hyper-autofluorescence bordered by a hypo-
autofluorescent halo, but may produce intermediate 
to decreased signal if there is overlying RPE atrophy or 
fibrovascular scarring. They are associated with a high 
risk for disease progression [91].
First described as dot-like spots seen on blue light pho-
tography, reticular pseudodrusen are subtle accumula-
tions of material above the RPE and visualized best on 
FAF, near-infrared FAF, or SD-OCT [92, 93]. They appear 
as small, round, elongated foci of hypo-autofluores-
cence bounded by interspersed hyper-autofluorescence 
in a reticular pattern [94]. Reticular pseudodrusen are 
associated with a high risk for progression to advanced 
disease involving choroidal neovascularization and/or 
geographic atrophy [95].
Geographic atrophy
Geographic atrophy is the hallmark of advanced non-
neovascular AMD. Lesions typically occur parafoveally, 
with foveal sparing. RPE atrophy and consequent loss 
of intrinsic fluorophores produces an area with a low to 
extinguished FAF signal with sharply demarcated borders. 
Lesions that include the fovea are more difficult to visual-
ize on FAF due to low baseline concentration of lipofuscin 
and absorption interference by macular pigment.
Geographic atrophy may be surrounded by perilesional 
hyper-autofluorescence, which represent areas of ongo-
ing RPE cell dysfunction, vertically superimposed RPE 
cells, and variable progression to atrophy [79, 96]. Phe-
notypes of perilesional hyper-autofluorescence include: 
none, focal, diffuse, banded, and patchy (Fig.  5). The 
diffuse phenotype is further delineated into reticular, 
branching, trickling, fine granular, and fine granular with 
peripheral punctate spots (GPS) patterns. Diffuse (espe-
cially the trickling pattern) and banded phenotypes are 
associated with a higher risk for disease progression. 
Fig. 5 Perilesional hyper-autofluorescence patterns in geographic atrophy in age-related macular degeneration. Geographic atrophy can be clas-
sified based on perilesional phenotypic FAF patterns. The subtype may impact prognosis, with diffuse and banded phenotypes portending greater 
risk for progression to advanced disease. Republished with permission of Association for Research in Vision and Ophthalmology, from “A subgroup 
of age-related macular degeneration is associated with mono-allelic sequence variants in the ABCA4 gene”, Lars G. Fritsche; Monika Fleckenstein; 
Britta S. Fiebig; Steffen SchmitzValckenberg; Almut BindewaldWittich; Claudia N. Keilhauer; Agnes B. Renner; Friederike Mackensen; Andreas Maner; 
Daniel Pauleikhoff; Christine Adrion; Ulrich Mansmann; Hendrik P. N. Scholl; Frank G. Holz; Bernhard H. F. Weber, vol 53, 2012; permission conveyed 
through Copyright Clearance Center, Inc
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Given the potential for understanding and predicting dis-
ease progression, FAF evaluation of atrophic AMD is an 
important clinical and research modality [97].
Choroidal neovascularization
Neovascular AMD is defined by the presence of choroi-
dal neovascularization, which is located either above the 
RPE (type 2), or under the RPE (type 1). Type 3 neovas-
cularization is located intraretinally and originates from 
the deep retinal capillary plexus [98].
Early choroidal neovascularization is not readily 
detectable on FAF, reflecting intact RPE and photore-
ceptor layers [99]. Classic choroidal neovascularization 
appears hypo-autofluorescent due to blockage of the 
RPE by the type 2 fibrovascular complex in the subreti-
nal space [100]. Occult type 1 neovascularization is also 
hypo-autofluorescent due to associated atrophy of the 
overlying RPE. Choroidal neovascularization may be bor-
dered by hyper-autofluorescence in 38 % of cases due to 
associated RPE proliferation or photoreceptor loss result-
ing in a window defect [101]. Hemorrhages and exudates 
are initially hypo-autofluorescent due to excitation light 
absorption, but then may become hyper-autofluorescent 
after undergoing organization.
Fundus autofluorescence patterns in non-neovascular 
AMD may predict the development of choroidal neovas-
cularization. Batoglu et al. found that the patchy pattern 
of early non-neovascular AMD had the strongest correla-
tion with progression to neovascular AMD, with 30.4 % 
of eyes developing choroidal neovascularization the 
mean follow-up period of 29.2 months [102, 103]. Linear 
and reticular patterns were also associated with increased 
risk for choroidal neovascularization [102].
RPE tears
RPE tears are a well-known complication of neovascu-
lar AMD, most commonly associated with large (greater 
than 600 microns in height) fibrovascular PEDs [104]. 
RPE tears can occur spontaneously or following photody-
namic therapy or anti-VEGF therapy due to accelerated 
contraction of the neovascular complex exerting traction 
on the RPE monolayer [105, 106].
RPE tears appear as a well-demarcated area of hypo-
autofluorescence due to absent RPE, with adjacent hyper-
autofluorescence in the form of rolled redundant RPE. 
Over time, tears remodel and resurfacing occurs, with 
recovery of autofluorescence extending centripetally 
from the borders toward the center (Fig.  6). The pro-
cess of resurfacing correlates with visual improvement 
and may benefit from treatment with anti-VEGF, though 
studies differ (Fig. 7) [105, 107, 108].
Differential diagnosis of age‑related macular degeneration
The wide variation in clinical presentation and severity of 
AMD, as well as its considerable overlap with other mac-
ular dystrophies, presents an interesting diagnostic chal-
lenge. Although drusen are the hallmark of AMD, they 
are not pathognomonic for the disease. Small drusen 
<63 µm represent normal aging rather than AMD [109]. 
Drusen should be differentiated from the irregular flecks 
of late onset Stargardt disease, which are character-
ized by intense hyper-autofluorescence on FAF. Drusen 
should also be differentiated from vitelliform lesions such 
as in Best dystrophy and adult onset vitelliform macular 
dystrophy, discussed below. Macular dystrophies that 
present with drusen or drusen-like deposits include 
Malattia Leventinese, Sorsby fundus dystrophy, and 
Fig. 6 Sequential fundus autofluorescence of an RPE tear. RPE tears (a) appear as well-demarcated central hypo-autofluorescence due to absent 
RPE with adjacent irregular hyper-autofluorescence corresponding to the retracted edges of RPE. Serial images obtained 3 weeks (b) and 1 year (c) 
later show resurfacing and remodeling of the lesion, with centripetal recovery of autofluorescence extending from the borders
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North Carolina macular dystrophy, all of which have an 
earlier age of onset and autosomal dominant inheritance. 
Geographic atrophy can resemble central areolar cho-
roidal dystrophy, late onset cone dystrophy, and central 
serous chorioretinopathy [110] and can be differentiated 
with the aid of FAF.
Central serous chorioretinopathy
CSCR most often presents as a serous retinal detachment 
that results from choroidal dysfunction and idiopathic 
leakage from the RPE into the subretinal space. Dur-
ing the initial presentation of CSCR, 72–96  % of cases 
show hypo-autofluorescence corresponding to the focal 
leakage site on fluorescein angiogram and to the area of 
serous retinal detachment, due to blockage by subretinal 
fluid [111–113]. A subset of patients may show local-
ized RPE detachment, corresponding with focal hyper-
autofluorescence. As the disease progresses, subsequent 
FAF images show granular hyper-autofluorescence, with 
increased number and size of hyper-autofluorescent dots 
corresponding to subretinal precipitates on OCT (Fig. 8a, 
b) [113]. This material represents photoreceptor debris 
and macrophages  accumulating in the subretinal space 
due to separation of the neurosensory layer from the RPE 
[114, 115]. The hyper-autofluorescent precipitates gravi-
tate inferiorly or collect at the borders of the detachment. 
In chronic cases lasting longer than 6  months, 85  % 
showed hypo-autofluorescent atrophic gravitational 
tracts that correlate to prior dependent subretinal fluid 
(Fig. 8c) [111, 114].
Near-infrared FAF is more sensitive for CSCR than 
conventional short-wavelength FAF, with short-wave-
length FAF revealing 83.2  % of abnormalities compared 
to 100 % by near-infrared FAF [116]. Ultra-widefield FAF 
can aid in the diagnosis and monitoring of CSCR [117]. 
Pang et al. found that 57 % of CSCR cases had extensive 
involvement of the peripheral retina. Abnormal hyper-
autofluorescent lesions in the periphery could indicate 
active disease and warrants further evaluation by SD-
OCT and indocyanine green angiography [118].
Macular dystrophies
Stargardt disease
Stargardt macular degeneration is the most common 
hereditary juvenile macular dystrophy. The disorder most 
commonly results from an autosomal recessive mutation 
in the ABCA4 gene, leading to defective outer segment 
degradation, lipofuscin accumulation, and central degen-
eration of the RPE and photoreceptor layer. Rare cases 
of autosomal dominant Stargardt disease result from 
mutations in the Elongation of Very Long Chain Fatty 
Acids (ELOVL4) gene [119]. Clinically, Stargardt disease 
Fig. 7 Sequential fundus autofluorescence of an RPE tear treated with aflibercept. RPE tears (a) appear as a well-demarcated central hypo-auto-
fluorescence due to absent RPE with adjacent irregular hyper-autofluorescence corresponding to the retracted edges of RPE. The patient received 
anti-VEGF therapy with half-dose aflibercept. Over time (b), the lesion shows evidence of slight remodeling and resurfacing, with early centripetal 
recovery of autofluorescence. Note the inferior extension of the tear. Photo courtesy of Nagiel A, Sadda S, Schwartz S, Sarraf D. “Resolution of a giant 
pigment epithelial detachment with half-dose aflibercept.” Retinal Cases and Brief Reports. Vol 9, Issue 4, 269–272. Promotional and commercial 
use of the material in print, digital or mobile device format is prohibited without the permission from the publisher Wolters Kluwer Health. Please 
contact healthpermissions@wolterskluwer.com for further information
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presents as foveal atrophy surrounded by flecks of yellow 
deposits, peripapillary sparing, and associated central 
vision loss [120].
Cideciyan et  al. synthesized a six stage model of dis-
ease pathogenesis that correlates well with FAF findings 
[121]. Early stages may demonstrate a general increase in 
lipofuscin and thus increased autofluorescent signal [120, 
122]. Intermediate stages show a high variation in mean 
intensity and texture (microscopic spatial variation in 
intensity) [121]. The disease then progresses to a pattern 
of chorioretinal atrophy resulting in macular hypo-auto-
fluorescence, surrounded by hyper-autofluorescent flecks 
(Fig. 9) [123]. Peripapillary sparing of the hyper-autofluo-
rescent flecks is highly suggestive of Stargardt disease. In 
advanced stages, complete degeneration and diffuse atro-
phy of RPE cells and photoreceptor death result in hypo-
autofluorescence and vision loss [123].
FAF may show areas of early atrophy and flecks not 
otherwise appreciated with fundus photography, suggest-
ing its utility in detecting early disease [123]. In addition, 
FAF correlates well with visual function, with normal 
macular autofluorescence associated with normal elec-
troretinography findings and good vision [120].
Best macular dystrophy
An early-onset macular dystrophy resulting in central 
vision loss, Best disease arises from autosomal dominant 
mutations in the BEST1 gene, encoding bestrophin-1. 
Shed photoreceptor debris and lipofuscin accumulate in 
the subretinal space, resulting in bilateral yolk-like lesions 
in the macula [124–126].
The progression of disease is classically separated 
into five stages of progression: previtelliform, vitel-
liform, pseudohypopyon, vitelliruptive, and atrophic, 
with progression at variable rates. In a retrospective, 
observational study, Querques et al. found that previtel-
liform lesions showed zero to minimal hyper-autofluo-
rescence. The vitelliform stage had well-circumscribed, 
homogenous hyper-autofluorescence in the macula. The 
pseudohypopyon stage showed a gravitational layer of 
hyper-autofluorescence settling under iso-autofluores-
cent fluid. The vitelliruptive stage showed a dark lesion 
bordered by condensations of hyper-autofluorescent 
material. The atrophic stage was characterized by diffuse, 
decreased signal due to chorioretinal atrophy [125].
Parodi et  al. characterized six different pheno-
types of Best disease with FAF, including normal, 
Fig. 8 Fundus autofluorescence of central serous chorioretinopathy. FAF (a) of a son with acute exacerbation of CSCR shows macular detachment 
due to acute CSCR, with hyper-autofluorescent material at the margin and inferior region of the detachment. SD-OCT (b) of the lesion shows a 
serous retinal detachment associated with a small pigment epithelial detachment. FAF of the patient’s asymptomatic father (c) incidentally revealed 
an atrophic hypo-autofluorescent gravitational tract from chronic inactive CSCR with hyper-autofluorescent margins
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hyper-autofluorescent, hypo-autofluorescent, patchy, 
multi-focal, and spoke-like patterns. The patchy subtype 
occurred most frequently, followed by the hyper-autoflu-
orescent, then hypo-autofluorescent patterns. These find-
ings did not correlate with the stages of progression or 
best corrected visual acuity [124].
Acute exudative polymorphous vitelliform maculopathy
Occurring as an idiopathic [127] or paraneoplastic 
syndrome [128, 129], acute exudative polymorphous 
vitelliform maculopathy (AEPVM) likely results from 
inflammatory or immune-mediated RPE dysfunction 
leading to lipofuscin accumulation and exudative retinal 
Fig. 9 Fundus autofluorescence of Stargardt disease. While fundus photography (a, b) and clinical examination may have non-specific findings, 
fundus autofluorescence (c, d) shows hyper-autofluorescent flecks with peripapillary sparing characteristic of the disease. The flecks surround a 
hypo-autofluorescent central macula corresponding to significant chorioretinal atrophy on SD-OCT (e)
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detachments [130]. AEPVM is characterized by multi-
focal, yellow-white, subretinal lesions associated with 
serous retinal detachments. These lesions are similar to 
the vitelliform deposits of Best disease, although genetic 
testing is negative for BEST1 mutations [131, 132]. FAF 
shows intense hyper-autofluorescence of the subretinal 
vitelliform material, which tends to gravitate inferiorly 
[133]. Lesions resolve gradually over weeks, with a cor-
responding decrease in autofluorescence [130].
Pattern dystrophies
Pattern dystrophies refer to a collection of late-onset, 
symmetric macular dystrophies with a clinically stable, 
benign course. Subtypes include adult onset vitelliform 
dystrophy, “butterfly” pigment dystrophy, reticular dys-
trophy, multifocal pattern dystrophy simulating fundus 
flavimaculatus, and fundus pulverulentus [134]. Pattern 
dystrophies are commonly associated with autosomal 
dominant mutations in the PRPH2 gene (formerly known 
as RDS, retinal degeneration slow gene) on chromosome 
6, which codes for a membrane glycoprotein on rod and 
cone photoreceptor outer segments [135]. As a result, 
yellow, orange, or gray material accumulates subretinally 
or at the level of the RPE, translating to hyper-autofluo-
rescent lesions [136].
Adult-onset vitelliform dystrophy predominantly 
results from mutations in the PRPH2 gene and less com-
monly the BEST1 genes [137]. This disease presents as 
small bilateral, subfoveal vitelliform lesions with a central 
clump of pigment that may evolve to RPE atrophy [138]. 
These vitelliform lesions emit increased autofluorescence 
[139, 140], while subsequent RPE atrophy results in hypo-
autofluorescence [138]. Furino et al. described three FAF 
patterns, including patchy, ring-like focal, and linear pat-
terns, but did not find a correlation with progression or 
visual function [141]. Around the same time, a slightly 
larger study by Parodi et al. identified three separate FAF 
patterns that progressed from normal, to focal, then to 
patchy hyper-autofluorescence, which correlated with 
visual acuity and retinal sensitivity. Of note, near-infrared 
FAF, which detects melanin, had a higher sensitivity than 
conventional short-wavelength autofluorescence, visual-
izing abnormalities in 100 versus 86 % of cases [142].
Multifocal pattern dystrophy simulating fundus flavi-
maculatus presents as irregular yellow flecks that are con-
centrated at the posterior pole and vascular arcades and 
that show hyper-autofluorescence on FAF. Classic “dot 
and halo” lesions appear as central hypo-autofluores-
cence surrounded by a hyper-autofluorescent halo [99]. 
Despite a similar appearance, multifocal pattern dystro-
phy can be differentiated from Stargardt disease by its 
autosomal dominant inheritance pattern, adult-onset, 
benign course (geographic atrophy is atypical with pat-
tern dystrophy), and lack of a dark choroid [143].
Other pattern dystrophies, especially “butterfly” 
lesions, reticular dystrophy, and fundus pulverulentus 
have not been well characterized on FAF imaging. How-
ever, the FAF findings can be remarkable and are more 
obvious than can be appreciated with examination by 
color photography. Moreover, FAF is a much less invasive 
procedure than fluorescein angiography and therefore is 
an important tool to reliably determine the diagnosis of 
macular dystrophies such as pattern dystrophy. Note that 
there is a high degree of phenotypic variability with pat-
tern dystrophy. Multiple patterns may manifest with the 
same mutation, or even in the same patient [99]. Further 
investigations to understand epigenetic and environmen-
tal effects on phenotype will help elucidate disease patho-
genesis and identify potential treatments.
Retinitis pigmentosa
Retinitis pigmentosa (RP) refers to a genetically hetero-
geneous group of retinal dystrophies characterized by 
the degeneration of rod photoreceptors. Mutations in the 
RHO (rhodopsin) gene are most common in autosomal 
dominant RP, mutations in the USH2A (Usher’s type 2) 
gene are most common in autosomal recessive RP, and 
RPGR and RP2 gene mutations are most common in 
X-linked RP. Patients may exhibit an annular scotoma 
in the mid-periphery that progressively extends towards 
the fovea, eventually involving cone photoreceptors and 
impinging on central vision. Electroretinography (ERG) 
is the gold standard modality for diagnosis and moni-
toring of disease progression, but loses clinical value in 
advanced disease [144]. As such, FAF is a viable supple-
mental imaging modality to monitor RP and correlate 
phenotype with genotype [145].
A retrospective, observational case series by Murakami 
et al. identified three subsets of RP on FAF, where 59 % of 
patients had a hyper-autofluorescent parafoveal ring not 
visible on funduscopic exam, 18 % had abnormal central 
hyper-autofluorescence extending centrifugally from the 
fovea, and 24  % had neither pattern [146]. The hyper-
autofluorescent ring, known as the Robson-Holder ring, 
corresponds to the border of inner/outer segment junc-
tion disruption (Fig.  10). OCT analysis shows complete 
photoreceptor loss outside of the ring, with the external 
limiting membrane in direct apposition to the RPE [147, 
148]. The ring itself corresponds to outer segment dys-
genesis and lipofuscin production, while normal retina 
lies within the ring [144, 149–151]. Spatial preservation 
of retinal sensitivity as measured by multifocal ERG cor-
relates with the radius of the autofluorescent ring, indi-
cating intact retinal sensitivity inside the ring but none 
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outside [152]. In addition, the size of the ring correlates 
with visual function as measured by both kinetic and 
automated perimetry; the more the ring encroached cen-
trally, the more constricted the visual field [153]. Serial 
imaging of this hyper-autofluorescent ring may help 
determine the stability or rate of progression of the dis-
ease, providing a useful tool for delineating prognosis in 
different patients [147].
Similar hyper-autofluorescent rings are also seen in 
several other retinal dystrophies, including Leber con-
genital amaurosis (LCA), bull’s eye maculopathy, X-linked 
retinoschisis, Best macular dystrophy, cone dystrophy, 
and cone-rod dystrophy [149]. This shared phenotype on 
FAF suggests an underlying common mechanism for the 
pathogenesis of retinal dystrophies.
Choroideremia
Choroideremia is an X-linked recessive defect in the 
CHM protein, which encodes the rab escort protein 
(REP1). Beginning in adolescence, male carriers experi-
ence night blindness and visual field constrictions due to 
centripetal atrophy of the choroid, RPE, and photorecep-
tor layer, though the macula is spared [154].
FAF shows bilateral, symmetric, midperipheral zones 
of hypo-autofluorescence due to RPE atrophy, which 
have scalloped edges with a preserved area of central 
stellate autofluorescence (Fig.  11) [155]. The atrophic 
zones extend with age and eventually involve the fovea 
[156]. Recent work on gene therapy for choroideremia 
has shown promising preclinical results and is cur-
rently undergoing clinical trials, with the first treatment 
administered in 2011 [157, 158]. FAF is an accurate 
structural marker that correlates with visual acuity and 
age, and may help identify candidates for gene therapy 
[154].
Interestingly, FAF of asymptomatic female carriers of 
the CHM mutation show a peripheral speckled pattern 
of hyper-autofluorescence corresponding to lipofus-
cin accumulation from photoreceptor degeneration and 
hypo-autofluorescence due to RPE atrophy [156, 159, 
160]. In conjunction with genetic testing, FAF is a useful 
for evaluating female relatives of affected patients.
Fundus albipunctatus
Fundus albipunctatus results from an autosomal reces-
sive defect in RDH5, which encodes a retinol dehydro-
genase in the RPE [161]. Patients are unable to oxidize 
11-cis-retinol to 11-cis-retinal, and this impairment of 
rhodopsin recycling delays the regeneration of photore-
ceptor pigments, manifesting as delayed dark adaptation 
and stationary night blindness [162]. Similar to Stargardt 
disease, fundus albipunctatus presents as a flecked retina 
syndrome, with white-yellow subretinal spots in the mid-
periphery on funduscopy.
As a hereditary defect in the visual cycle, fundus albi-
punctatus causes decreased lipofuscin production and 
severely attenuated background autofluorescence [163]. 
Images appear grainy [164]. FAF may also show hyper-
autofluorescent foci corresponding to the white dots, 
though not all lesions produce autofluorescence (Fig. 12) 
[165]. SD-OCT through these lesions reveal dome 
shaped hyperreflective material extending from the RPE 
Fig. 10 Robson-holder ring in retinitis pigmentosa. FAF (a) of retinitis pigmentosa shows an area of normal preserved retina at the posterior fundus 
bordered by a hyper-autofluorescent Robson-holder ring. Mottled hypo-autofluorescence outside the ring represents photoreceptor degeneration. 
These details are visible on FAF but not on fundus photography (b). Image courtesy of Heidelberg Engineering
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past the photoreceptor layer [156]. Hyper-autofluores-
cent crescents or concentric parafoveal rings have also 
been reported [165].
Fundus albipunctatus must be differentiated from dis-
eases with similar presentations. Retinitis punctata albes-
cens is also associated with white punctate retinal lesions 
Fig. 11 Fundus autofluorescence of choroideremia. Wide-field color fundus photography (a, b) shows a pale fundus with zones of choroidal 
atrophy in the mid-periphery, revealing the sclera underneath. Wide-field fundus autofluorescence (c, d) demonstrates corresponding zones of 
hyper-autofluorescence given the autofluorescent properties of the sclera. Note the central stellate island of preserved choriocapillaris and RPE in 
each eye that is characteristic of choroideremia. Photo credit: Srinivas Sadda, MD
Fig. 12 Fundus autofluorescence of fundus albipunctatus. Fundus photography (a) demonstrates multifocal white flecks in the midperiphery with 
macular sparing. FAF (b) shows profoundly decreased background autofluorescence and a grainy resolution. Photo credit: Sam Yang, MD
Page 18 of 25Yung et al. Int J Retin Vitr  (2016) 2:12 
on the retina and night blindness. This disease is due to 
an autosomal recessive mutation in RLBP1 encoding 
CRALBP, which binds to 11-cis-retinol and 11-cis-retinal 
during the visual cycle [166]. However, retinitis punctata 
albescens is a severe progressive retinal dystrophy with 
narrowed vessels, pigmentary degeneration, and visual 
field loss [166]. Meanwhile, RPE65 encodes an isomer-
ase which acts one step upstream of retinol dehydro-
genase in the visual cycle and also results in decreased 
background autofluorescence on FAF [167]. In contrast 
to fundus albipunctatus, mutations in RPE65 result in a 
more severe disease course and are associated with LCA 
and early onset rod-cone dystrophy [168].
White dot syndromes
White dot syndromes refer to a diverse spectrum of inflam-
matory chorioretinopathies characterized by multifocal, 
small, yellow-white lesions scattered throughout the pos-
terior pole and/or peripheral fundus. Despite this shared 
phenotypic presentation, the individual diseases are not 
related in pathogenesis, management, or prognosis [169].
Multiple evanescent white dot syndrome (MEWDS)
This disease affects young, healthy women 20–50  years 
old and manifests as a self-limited, unilateral presentation 
with multifocal 100–200 µm white spots scattered in the 
paramacular and mid-peripheral fundus [170].
On FAF, the multifocal lesions have increased signal 
strength due to photoreceptor loss and unmasking of 
natural RPE autofluorescence (Fig.  13) [80, 171]. Hypo-
autofluorescent foci at the fovea correspond with foveal 
granularity on exam and accumulation of hyper-reflective 
material interdigitating between the RPE and photore-
ceptor layer on OCT [170]. FAF reveals more lesions than 
on clinical exam or FA, though less than seen on indocya-
nine green angiography [172, 173], and FAF may be used 
in lieu of FA and ICG due to its high sensitivity, greater 
ease of use, and non-invasive nature of administration.
Punctate inner choroidopathy (PIC)
A diagnosis of exclusion, PIC refers to the presence of 
multifocal choroidal lesions in the absence of uveitis or 
presumed ocular histoplasmosis (POHS). This disease 
tends to occur in young, myopic women and is associated 
with the development of choroidal neovascularization 
and subsequent vision loss [174].
Active PIC lesions present as sub-RPE chorioretinal 
nodules, which may display minimal hyper-autofluo-
rescence or become hypo-autofluorescent spots as the 
nodules break through the RPE [175]. These hypo-auto-
fluorescent spots often have a hyper-autofluorescent mar-
gin, corresponding to a window defect of surrounding 
photoreceptor loss on SD-OCT [171, 175]. Meanwhile, 
the majority of atrophic lesions appear as isolated hypo-
autofluorescent spots. A subset of patients present with 
hypo-autofluorescent spots associated with diffuse hyper-
autofluorescent patches, 90 % of which were identified as 
concurrent MEWDS on multimodal imaging [171]. Simi-
lar to the choroidal neovascularization seen in ARMD, 
choroidal neovascularization in PIC presents as foci of 
slight hypo- or hyper-autofluorescence with a surround-
ing hyper-autofluorescent ring [175]. Additional reports 
have found that FAF and ultra-widefield FAF can be use-
ful for detecting changes in eyes with PIC that are not evi-
dent on clinical exam [176, 177].
Drug toxicity
Hydroxychloroquine toxicity
Hydroxychloroquine is an inexpensive and well-tolerated 
anti-inflammatory agent. However, the risk for ocular tox-
icity rises sharply with cumulative dose, especially with 
doses over 1000 g [178]. In addition, because the drug is 
not retained in fatty tissues, individuals who are obese or 
have short stature are at risk for overdosage [179].
In Caucasian populations, hydroxychloroquine tox-
icity causes irreversible parafoveal photoreceptor loss 
with foveal sparing, resulting in paracentral scotomas. 
FAF shows a hyper-autofluorescent parafoveal ring 
Fig. 13 Ultra-widefield imaging of multiple evanescent white dot 
syndrome (MEWDS). Ultra-widefield FAF of active disease (a) with 
multifocal hyper-autofluorescence and resolution (b) 6 weeks later
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corresponding to photoreceptor damage, which decreases 
in signal strength over time due to RPE atrophy (Fig. 14b) 
[180]. However, Asian populations tend to show a pericen-
tral pattern of photoreceptor loss occurring well outside the 
parafoveal zone, with an odds ratio of 27.1 compared to the 
parafoveal pattern (Fig. 14d). Pericentral presentations tend 
to be diagnosed at higher cumulative dosages and at later 
stages of disease than parafoveal presentations, indicating 
that pericentral patterns are not as easily recognized on 
screening [181]. Late manifestations of the disease include 
bilateral bull’s eye maculopathy. If the drug regimen is not 
halted, the area of depigmentation may spread to involve 
the central fovea and even the entire fundus.
Screening guidelines for hydroxychloroquine toxicity 
by the American Academy of Ophthalmology recom-
mend annual examinations starting at 1 year of use and 
annual evaluation with diagnostic testing including SD-
OCT, perimetry, and mf-ERG [179, 182]. Compared to 
multi-focal ERG, FAF has a sensitivity of 73.7  % and is 
best used as a component of multi-modal imaging in the 
screening process [183, 184].
Didanosine‑induced retinal toxicity
Didanosine (DDI) is a nucleoside reverse transcriptase 
inhibitor (NRTI) that was previously one of the main-
stays for HIV treatment. However, this drug also inhib-
its the synthesis of mitochondrial DNA (mtDNA), 
resulting in mitochondrial toxicity and in rare cases 
precipitating a retinopathy similar to those seen in 
other mitochondrial disorders [185]. In the six cases 
described in the literature, adult DDI toxicity pre-
sents as sharply demarcated, midperipheral, concen-
tric chorioretinal atrophy [186–189]. Widefield FAF 
is essential in making the diagnosis and shows a char-
acteristic mottled hyper-autofluorescence and hypo-
autofluorescence in the midperiphery that spares the 
Fig. 14 Spectrum of hydroxychloroquine toxicity on FAF. Compared to a normal fundus (a), hydroxychloroquine toxicity may manifest in a parafo-
veal pattern (b), mixed pattern (c), or pericentral pattern of characteristic FAF abnormalities (d). With kind permission from Elsevier: Ophthalmology, 
“Pericentral retinopathy and racial differences in hydroxychloroquine toxicity,” 2015, pp. 110–116, Melles and Marmor, Fig. 1
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central macula (Fig.  15) [187]. More advanced cases 
will show confluent midperipheral hypo-autofluores-
cent atrophy in each eye.
Deferoxamine‑induced retinal toxicity
As an iron chelator, deferoxamine is used to treat iron 
overload, such as in patients requiring chronic transfu-
sions. Although the mechanism is not well understood, 
deferoxamine may injure the retina through direct 
toxic effects on RPE cells or chelation-induced iron, 
zinc, or copper deficiencies [190–192]. Deferoxamine 
retinopathy has various reported funduscopic manifes-
tations, including pigmentary changes with RPE mot-
tling, vitelliform lesions, and bull’s eye maculopathy 
[193–195].
FAF is more sensitive than ophthalmoscopy for detect-
ing deferoxamine-induced retinal alterations and can be 
used to screen patients for toxicity and identify patients 
at high-risk for vision loss [196]. In a prospective case 
control study of 197 patients with β-thalassemia who 
received deferoxamine, 18 patients developed FAF 
abnormalities. Viola et al. characterized four distinct FAF 
patterns: minimal change, focal, patchy, and speckled 
patterns [196]. Patients with the minimal change pattern 
had the lowest incidence of vision deterioration, while 
patients with the patchy or speckled pattern had the most 
severe vision loss [196].
Conclusion
Fundus autofluorescence provides information on the meta-
bolic state and overall health of the RPE, and indirectly, the 
photoreceptor layer. Many imaging systems are available, 
each utilizing different optical properties that have distinct 
advantages and disadvantages. FAF is now an important 
tool for the evaluation of the prognosis and progression of 
geographic atrophy in AMD and for the phenotypic char-
acterization of retinal dystrophies. FAF is also critical in the 
diagnosis of white dot syndromes and drug toxicities, among 
other entities. The applications of this simple, noninvasive 
imaging modality will continue to evolve and may replace 
more invasive procedures such as fluorescein angiography.
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RP: retinitis pigmentosa; ERG: electroretinography; LCA: leber congenital 
amaurosis; MEWDS: multiple evanescent white dot syndrome; PIC: punctate 
inner choroidopathy; POHS: presumed ocular histoplasmosis syndrome; 
DDI: didanosine; NRTI: nucleoside reverse transcriptase inhibitor; mtDNA: 
mitochondrial DNA.
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